Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HRH1 | P35367 | 4/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | SCN4A | P35499 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27842300 | 0.81 | HRH1 (0.54) | TSHRHTR2AHRH1TAAR1DPP4 | |
| SCHEMBL4660217 | 0.79 | ALDH1A1 (0.40) | HTR2AHRH1TAAR1 | |
| SCHEMBL4194601 | 0.79 | HDAC3 (0.35) | HTR2AHRH1TAAR1MTORRAB9A | |
| SCHEMBL1645203 | 0.78 | TSHR (0.42) | TSHRHTR2AHRH1TAAR1MTOR | |
| SCHEMBL3454935 | 0.74 | TRPA1 (0.38) | HTR2AHRH1TAAR1MTORRAB9A | |
| SCHEMBL1270652 | 0.72 | TAAR1 (0.42) | TSHRHTR2AHRH1TAAR1MTOR | |
| SCHEMBL4661596 | 0.71 | HTT (0.32) | TSHRSMN1; SMN2HTR2AHRH1 | |
| SCHEMBL4361027 | 0.71 | KCNA3 (0.39) | TSHRSMN1; SMN2HTR2AHRH1TAAR1 | |
| SCHEMBL9339406 | 0.69 | TAAR1 (0.50) | TSHRHTR2AHRH1TAAR1DPP4 | |
| SCHEMBL2118480 | 0.69 | TAAR1 (0.39) | TSHRHTR2AHRH1TAAR1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326936-A1 | ARTICLES INCLUDING SURFACE COATINGS AND METHODS TO PRODUCE THEM | MAXTERIAL INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12173166-B2 | Articles including surface coatings and methods to produce them | MAXTERIAL, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230295827-A1 | COATINGS AND COATED SURFACES INCLUDING LOW-SURFACE ENERGY INORGANIC PARTICLES | MAXTERIAL INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11542621-B1 | Coatings and coated surfaces including low-surface energy inorganic particles | MAXTERIAL, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3691894-A1 | ARTICLES INCLUDING SURFACE COATINGS AND METHODS TO PRODUCE THEM | Maxterial, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-111405980-A | Article comprising a surface coating and method for producing the same | 麦克斯特里尔有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20190186035-A1 | ARTICLES INCLUDING SURFACE COATINGS AND METHODS TO PRODUCE THEM | MAXTERIAL INC (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2019067950-A1 | ARTICLES INCLUDING SURFACE COATINGS AND METHODS TO PRODUCE THEM | MAXTERIAL, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20180028029-A1 | DRYING APPARATUS COMPRISING A HYDROPHOBIC MATERIAL | HAGHDOOST ATIEH (US) | 2018-02-01 | — | — | US | disclosed |
| US-20170334170-A1 | ARTICLES INCLUDING ADHESION ENHANCING COATINGS AND METHODS OF PRODUCING THEM | HAGHDOOST ATIEH (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170190139-A1 | COATINGS AND COATED SURFACES WITH SELECTED SURFACE CHARACTERISTICS AND FEATURES | HAGHDOOST ATIEH (US) | 2017-07-06 | — | — | US | disclosed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1919929-A4 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007019221-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | TSHR 3201/4885SMN1; SMN2 259/4885HTR2A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.